figshare
Browse
1/1
5 files

Oncogenic BRAF mutation induces DNA methylation changes in a murine model for human serrated colorectal neoplasia

dataset
posted on 2017-12-13, 14:22 authored by Catherine E. Bond, Cheng Liu, Futoshi Kawamata, Diane M. McKeone, Winnie Fernando, Saara Jamieson, Sally-Ann Pearson, Alexandra Kane, Susan L. Woods, Tamsin R. M. Lannagan, Roshini Somashekar, Young Lee, Troy Dumenil, Gunter Hartel, Kevin J. Spring, Jennifer Borowsky, Lochlan Fennell, Mark Bettington, Jason Lee, Daniel L. Worthley, Barbara A. Leggett, Vicki L. J. Whitehall

Colorectal cancer is a major cause of cancer death and approximately 20% arises within serrated polyps, which are under-recognized and poorly understood. Human serrated colorectal polyps frequently exhibit both oncogenic BRAF mutation and widespread DNA methylation changes, which are important in silencing genes restraining neoplastic progression. Here, we investigated whether in vivo induction of mutant Braf is sufficient to result in coordinated promoter methylation changes for multiple cancer-related genes. The BrafV637E mutation was induced in murine intestine on an FVB;C57BL/6J background and assessed for morphological and DNA methylation changes at multiple time points from 10 days to 14 months. Extensive intestinal hyperplasia developed by 10 days post-induction of the mutation. By 8 months, most mice had murine serrated adenomas with dysplasia and invasive cancer developed in 40% of mice by 14 months. From 5 months onwards, Braf mutant mice showed extensive, gene-specific increases in DNA methylation even in hyperplastic mucosa without lesions. This demonstrates that persistent oncogenic Braf signaling is sufficient to induce widespread DNA methylation changes. This occurs over an extended period of time, mimicking the long latency followed by rapid progression of human serrated neoplasia. This study establishes for the first time that DNA methylation arises slowly in direct response to prolonged oncogenic Braf signaling in serrated polyps; this finding has implications both for chemoprevention and for understanding the origin of DNA hypermethylation in cancer generally.

Funding

This work was supported by the Australian National Health and Medical Research Council (NHMRC1050455, 1063105, 1110941, 1081852), Pathology Queensland, Royal Brisbane and Women's Hospital Research Foundation, Cancer Council of Queensland, Cure Cancer Australia, Viertel Foundation and Cancer Council SA's Beat Cancer Project on behalf of its donors and the State Government of South Australia through the Department of Health. CL is funded by an Australian Postgraduate Award, FK is funded by the Uehara Memorial Foundation Fellowship, DW is funded by an NHMRC Career Development Fellowship and VW is funded by a Gastroenterological Society of Australia Senior Research Fellowship.

History